Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
Public ClinicalTrials.gov record NCT03916185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
Study identification
- NCT ID
- NCT03916185
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Interventions
- Placebo Biological
- RSV 276 Vaccine Biological
- RSV 6120/ΔNS2/1030s Vaccine Biological
- RSV ΔNS2/Δ1313/I1314L Vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Months to 25 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2019
- Primary completion
- Jan 21, 2024
- Completion
- Apr 24, 2024
- Last update posted
- Feb 20, 2025
2019 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicine at UCLA NICHD CRS | Los Angeles | California | 90095-1752 | — |
| University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program | San Diego | California | 92103 | — |
| Univ. of Colorado Denver NICHD CRS | Aurora | Colorado | 80045 | — |
| Emory University School of Medicine NICHD CRS | Atlanta | Georgia | 30322 | — |
| Rush Univ. Cook County Hosp. Chicago NICHD CRS | Chicago | Illinois | 60612 | — |
| Lurie Children's Hospital of Chicago (LCH) CRS | Chicago | Illinois | 60614-3393 | — |
| University of Maryland School of Medicine Center for Vaccine Development CRS | Baltimore | Maryland | 21201 | — |
| The Children's Mercy Hospital CRS | Kansas City | Missouri | 64108-4619 | — |
| Center for Vaccine Development CRS | St Louis | Missouri | 63104 | — |
| SUNY Stony Brook NICHD CRS | Stony Brook | New York | 11794 | — |
| Jacobi Med. Ctr. Bronx NICHD CRS | The Bronx | New York | 10461 | — |
| Duke Vaccine and Trials Unit CRS | Durham | North Carolina | 27703 | — |
| Gamble Center for Clinical Studies CRS | Cincinnati | Ohio | 45229 | — |
| Baylor College of Medicine/ Texas Children's Hospital NICHD CRS | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03916185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03916185 live on ClinicalTrials.gov.